Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Vryalar

- PMLiVE

Allergan Aesthetics launches Skin Quality Index for aesthetic consultations

Spanning four dimensions of skin health, the framework introduces 15 terms and definitions

- PMLiVE

MHRA authorises first in new class of treatment for endometriosis symptoms

The chronic condition affects approximately 176 million women worldwide

- PMLiVE

Alkermes’ new antipsychotic clears FDA advisory committee hurdle

Target action date for FDA decision is due on 15 November

- PMLiVE

FDA approves Allergan’s biodegradable glaucoma implant drug

Reduces intraocular pressure in glaucoma or ocular hypertension

- PMLiVE

Allergan and Editas claim a CRISPR first in inherited blindness study

Partners are first to use CRISPR to edit cells inside the body

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Resonant Group

- PMLiVE

AbbVie says Allergan takeover delayed by FTC verdict

Merger now likely to complete in second quarter rather than first

- PMLiVE

AbbVie/Allergan merger faces renewed public opposition despite divestments

Consumer groups and public interest organisations raise new concerns

- PMLiVE

Botox strength bolsters Allergan ahead of AbbVie takeover

Speciality drugmaker posted a 6.6% sales increase in the last quarter

- PMLiVE

Troubled Alkermes eyes November OK for new antipsychotic

Review begins for potential schizophrenia and bipolar I disorder drug

- PMLiVE

AbbVie creates new aesthetics division amid Allergan takeover

New separate business unit will operate own R&D functions

- PMLiVE

Allergan gets FDA nod for first oral CGRP drug for migraine

Extended use into acute treatment of migraine

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links